Scarica l'app Stockscreener
53.03
5.25%
-2.94
Dopo l'orario di chiusura:
52.90
-0.13
-0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$55.97
Aprire:
$55.755
Volume 24 ore:
3.02M
Relative Volume:
1.16
Capitalizzazione di mercato:
$13.33B
Reddito:
$2.38B
Utile/perdita netta:
$833.42M
Rapporto P/E:
17.58
EPS:
3.0172
Flusso di cassa netto:
$917.69M
1 W Prestazione:
-4.23%
1M Prestazione:
-2.54%
6M Prestazione:
+28.22%
1 anno Prestazione:
+46.41%
Intervallo 1D:
$52.79
$56.18
Intervallo di 1 settimana:
$52.79
$56.85
Portata 52W:
$33.76
$57.57
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
53.03 | 14.03B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis Inc (EXEL) Cash Flow - TradingKey
Exelixis Inc (EXEL) Income Statement - TradingKey
Exelixis Inc (EXEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exelixis Inc (EXEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exelixis, Inc. Revenue Breakdown – BX:EX9 - TradingView
Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exelixis Inc (EXEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exelixis, Inc. Revenue Breakdown – LSX:936718 - TradingView
EXEL|Exelixis Inc|Price:55.370|Chg%:-0.280 - TradingKey
EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q1 FY2026 earnings call transcript - Yahoo Finance
Exelixis Inc (EXEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EXEL Maintained by Morgan Stanley -- Price Target Raised to $53 - GuruFocus
Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $64 - Moomoo
EXEL stock trades steadily as Exelixis leans on expanding oncology revenue - Ad-hoc-news.de
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 - BioSpace
What Happened at Exelixis (NASDAQ:EXEL) Before Results Date? - Kalkine Media
Exelixis to release Q2 2026 financial results on August 5 - scanx.trade
Lobbying Update: $560,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Exelixis (EXEL) earnings expected to grow: Should you buy? - MSN
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
(EXEL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
What's Driving Exelixis' Recent Momentum and 2026 Outlook - Kavout | AI
Exelixis (EXEL) Stock May Be Undervalued Following FDA Review Uncertainty - simplywall.st
EXEL Maintained by Barclays -- Price Target Raised to $49 - GuruFocus
Analysts Conflicted on These Healthcare Names: Exelixis (EXEL) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Exelixis, Inc. (EXEL) hit a 52-week high, can the run continue? - MSN
Daily Brief Industrials: Archion, Baycurrent, easyJet PLC, Hanjin KAL Corp, World-Link Logistics (Asia), Genneia, Robotechnik Intelligent Te-A, Shenzhen Megmeet Electrical , Exelixis Inc, Rush Enterprises Inc Cl A and more - Smartkarma
Daily Brief Health Care: Apnimed, Cigna Group, Exelixis Inc, Scribe Therapeutics, CSPC Pharmaceutical and more - Smartkarma
Daily Brief Financials: SBI Funds Management Ltd, Choice International, Kotak Mahindra Bank, Exelixis Inc, Bank Mandiri Persero, Ryan Specialty Holdings and more - Smartkarma
symbol__ Stock Quote Price and Forecast - CNN
EXEL Maintained by Wells Fargo -- Price Target Raised to $49.00 - GuruFocus
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth In The Oncology Biotech Space - DirectorsTalk Interviews
Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued? - Yahoo Finance
Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run - Yahoo Finance
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? - Yahoo Finance
Exelixis Announces Zanzalintinib in Combinati - Moomoo
Exelixis: STELLAR-303 Results Mixed, STELLAR-304 Success Likely (NASDAQ:EXEL) - Seeking Alpha
Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In? - Yahoo Finance
Handa, Intas Face Patent Suits Over Exelixis Cancer Drug - Law360
Exelixis focuses on oncology pipeline as Nasdaq-listed biotech pursues growth - ad-hoc-news.de
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June - AOL.com
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists - Investor's Business Daily
EXEL Maintained by RBC Capital -- Price Target Raised to $46.00 - GuruFocus
Exelixis Inc stock hits all-time high at 56.22 USD - Investing.com
Exelixis Inc stock hits all-time high at 56.22 USD By Investing.com - Investing.com Nigeria
Truist Financial Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $56 - Moomoo
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exelixis Inc Azioni (EXEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Eckhardt Sue Gail | Director |
Jun 01 '26 |
Sale |
50.14 |
9,812 |
491,974 |
16,079 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):